<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:05:24Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/31445" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/31445</identifier><datestamp>2026-09-24T22:43:27Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Miller, Matthew S.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">D'Agostino, Michael R.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-03-27T19:15:28Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2025-03-27T19:15:28Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/31445</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/14420</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">The COVID-19 pandemic underscored the urgent need for innovative vaccine platforms&#xd;
capable of addressing rapidly evolving SARS-CoV-2 variants and enhancing pandemic&#xd;
preparedness. Current intramuscularly administered vaccines, which solely target the spike&#xd;
protein, face diminished efficacy against antibody-escaping variants and provide limited&#xd;
protection for high-risk populations. This thesis presents three studies aimed at improving&#xd;
active and passive mucosal vaccination strategies against SARS-CoV-2.&#xd;
First, we developed and evaluated trivalent human (HuAd) and chimpanzee (ChAd)&#xd;
adenovirus-vectored COVID-19 vaccines encoding the spike, nucleocapsid, and RdRP&#xd;
antigens. In murine models, respiratory mucosal (RM) immunization induced robust tripartite&#xd;
immunity comprised of local and systemic antibody responses, mucosal tissue-resident&#xd;
memory T cells, and trained innate immunity. Moreover, RM vaccination conferred&#xd;
protection against both ancestral SARS-CoV-2 and emerging variants of concern (V oCs),&#xd;
highlighting the potential of Ad-vectored mucosal vaccines as next-generation solutions to&#xd;
address shortcomings in first-generation COVID-19 vaccines.&#xd;
In the second study, we extended this platform to human volunteers, revealing that repeated&#xd;
intramuscular mRNA immunization alone fails to elicit sufficient RM immunity, even in&#xd;
individuals with prior breakthrough infection. To bridge this gap, we administered our next-&#xd;
generation SARS-CoV-2 vaccine candidates via inhaled aerosol which was safe and well-&#xd;
tolerated. A single aerosolized dose induced airway T cell, antibodies, and innate immune&#xd;
memory, with cross-reactive T cells and antibodies against SARS-CoV-2 XBB.1.5. We also explored peripheral biomarkers that may serve as surrogates for the induction of robust RM&#xd;
immunity.&#xd;
Finally, in a complementary approach, we investigated aptamer nanomaterials based on&#xd;
TMSA52, a homotrimeric DNA aptamer engineered for broad neutralization of SARS-CoV-&#xd;
2 VoC. When RM administered to mice, TMSA52 showed protective efficacy comparable to&#xd;
a monoclonal antibody, offering a cost-effective, scalable alternative for passive&#xd;
immunization. Together, these studies underscore the promise of RM vaccination strategies&#xd;
as critical innovations to enhance global pandemic preparedness.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">The COVID-19 pandemic caused immense burden on global healthcare systems, highlighting&#xd;
the global vulnerability to zoonotic respiratory viruses. This burden was partially alleviated&#xd;
by the rapid design and implementation of spike-based COVID-19 vaccines, however they&#xd;
soon lost efficacy due to the emergence of SARS-CoV-2 variants. Therefore, there is an urgent&#xd;
need to develop active and passive vaccine platforms resistant to antigenic changes in spike.&#xd;
We developed an inhaled vaccine expressing multiple SARS-CoV-2 antigens that generates&#xd;
variant-proof immunity in the airways of mice and humans. However immune compromised&#xd;
populations may not respond well to vaccines and are at risk of progressing to severe COVID-&#xd;
19. Consequently, we have developed DNA aptamers that mimic antibodies to neutralize&#xd;
SARS-CoV-2 variants and tested their safety and efficacy following intranasal administration&#xd;
in mice. Overall, we have expanded the toolkit to combat SARS-CoV-2, and importantly these&#xd;
platforms are readily adaptable to any future pandemic threats.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Vaccines</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">SARS-CoV-2</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">ACTIVE AND PASSIVE VACCINATION STRATEGIES AGAINST SARS-COV-2</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>